MELBOURNE, June 10, 2026, 01:04 AEST
Pro Medicus Ltd shares kept much of their strong bounce Tuesday, as the market looked at a new AI product push from its Visage Imaging arm but weighed it against Pro Medicus’s high valuation. The stock ended up 15 cents at A$165.79, trading between A$160.29 and A$167.78, with about 341,000 shares moving.
Visage is set to pitch its latest radiology software at SIIM26 in Pittsburgh this week. The company plans to show Visage 7 | CloudPACS, a cloud-based system for storing and displaying medical scans, along with Visage 7 | Reporting, an AI-optimised reporting tool. Visage said first North American go-lives are expected in either the third or fourth quarter of 2026. Co-founder and global chief technology officer Malte Westerhoff called it “an exciting milestone for Visage 7.” BioSpace
Pro Medicus shares are up 25.35% in the last week, bouncing after new U.S. contract news. The company last week announced a five-year, A$16 million renewal with The Ohio State University Wexner Medical Center. It’s not just about a product demo, Intelligent Investor data show.
Ohio’s renewal adds Visage 7 Workflow and Visage 7 Cardiology Imaging, ups minimums and per-transaction fees, and shifts to a transaction-based setup that could pay off if volumes grow. CEO Sam Hupert said the deal boosts financial-year renewals to A$141 million and shows customers are still looking to “retire legacy solutions.” ASX Announcements
Pro Medicus has been selling medical-imaging software since 1983, targeting hospitals and imaging practices with products in radiology IT, PACS, AI and related areas. The Visage unit, which Pro Medicus bought in 2009, now drives its global imaging push. Visage has offices in Melbourne, Berlin and San Diego.
Pro Medicus says its financial base is solid. Back in February, the company posted first-half revenue of A$124.8 million, up 28.4%. Underlying profit before tax rose 29.7% to A$90.7 million. The underlying EBIT margin was 73%. Net profit came in at A$171.2 million, though that number was boosted by a A$149.1 million unrealised gain from a hybrid debt-and-equity investment in 4DMedical.
Hupert told investors at the half-year result that “revenues will flow as each implementation comes on stream.” A string of planned go-lives before year-end is expected. The focus for the market now is whether those signed contracts get delivered, and whether the new systems actually keep generating transaction revenue. Pro Medicus
Competition is heating up. Visage is pushing its “one platform” pitch as big health systems look to combine imaging archives, viewers and workflow. ASX-listed Mach7 Technologies offers an enterprise imaging platform with a vendor-neutral archive and eUnity viewer. 4DMedical stays focused on lung imaging with software and hardware, not as a head-to-head PACS competitor. Mach7 Technologies
ASX 200 edges lower, weighed by materials. The S&P/ASX 200 was down 0.24% Tuesday, with materials stocks pulling the index lower. The ASX cash market reopened after being shut Monday for the King’s Birthday holiday.
But Pro Medicus has little margin for error. The stock is still off 24.86% for calendar 2026 and has dropped 42.85% this financial year, even after the seven-day rally. Google Finance puts its price-to-earnings ratio near 74. Any delay in North American go-lives, softer scan volumes, or tougher price competition from imaging-software rivals could see the rebound give way to profit-taking.
Investors are keeping an eye on SIIM26 to see if it drives new pipeline deals, and on U.S. renewals to see if bigger minimums still come through. There’s also some wait-and-see around whether AI pushes hospitals to stick with Visage or look elsewhere. Pro Medicus shares suggest the company has time left, but the margin for error is thin.
